A Phase 2 interventional study of Romiplostim (AMG-531) in Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Kyowa Kirin Co., Ltd.. Completed. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing romiplostim in Purpura, Thrombocytopenic — 1 open to participants now, 1 under way, none of them phase 3. romiplostim · Purpura, Thrombocytopenic.
Among the 11 studies testing romiplostim in Purpura, Thrombocytopenic, this one is the 11th largest by enrollment, is one of 3 that started in 2006, is the only one in phase 2, and was the 5th registered.
32 studies on the registry are indexed under Purpura, Thrombocytopenic; 6 are open to participants now.
Browse Purpura, Thrombocytopenic studies →1 of the 11 studies testing romiplostim in Purpura, Thrombocytopenic is open now, in 1 country. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 4 Purpura, Thrombocytopenic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 20 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 7
First in 2002; this study’s year is marked. 3 started in 2006.
This study's enrollment of 12 is below the median of 54 across 22 interventional studies indexed under Purpura, Thrombocytopenic.
Median enrollment 62 across the 11 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 11 have an industry lead sponsor. The 3 most frequent:
Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 8 are open to participants now.
Kyowa Kirin Co., Ltd. has 2 studies filed under Purpura, Thrombocytopenic — fewer than ten, so there is no comparison to draw.
1 of the studies testing romiplostim in Purpura, Thrombocytopenic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies testing romiplostim in Purpura, Thrombocytopenic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.
The purpose of the study is to evaluate the efficacy of starting dose of AMG 531 as measured by platelet counts by cohort dose-escalation design.
Inclusion Criteria: - Japanese patients with diagnosis of ITP according to the diagnostic criteria proposed by Research Committee for Idiopathic Hematopoietic Disorders of the Ministry of health, labor and welfare Exclusion Criteria: - Documented diagnosis of arterial thrombosis in the previous year; history of venous thrombosis and receiving anticoagulation therapy
Drug: Romiplostim (AMG-531)
Romiplostim (AMG-531)
Incidence of all adverse events including evaluation of antibody status
Time frame: 1 year
Proportion of subjects who achieve a platelet response
Time frame: 2 weeks
No study locations are listed for this record.
The record gives a start of Feb 2006, a primary completion of Nov 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim